lanosten-3-ol-32-al: RN given refers to (3beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3beta-hydroxylanost-8-en-32-al : A tetracyclic triterpenoid that is lanost-8-ene carrying hydroxy and oxo substituents at positions 3beta and 30 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 15698824 |
| CHEBI ID | 87060 |
| SCHEMBL ID | 14836473 |
| MeSH ID | M0101287 |
| Synonym |
|---|
| 59200-40-7 |
| 32-oxo-dhl |
| 4,4-dimethyl-14alpha-formyl-5alpha-cholesta-8-en-3beta-ol |
| 4,4-dimethyl-14alpha-formyl-5alpha-cholest-8-en-3beta-ol |
| LMST01010223 |
| 3beta-hydroxylanost-8-en-32-al |
| lanost-8-en-30-al, 3-hydroxy-, (3beta)- |
| lanosterol-32-aldehyde |
| 3-hydroxylanost-8-en-32-al |
| lanosten-3-ol-32-al |
| 32-oxo-24,25-dihydrolanosterol |
| 3-beta-hydroxylanost-8-en-32-aldehyde |
| SCHEMBL14836473 |
| (3beta)-3-hydroxylanost-8-en-30-al |
| CHEBI:87060 |
| 3-b-hydroxylanost-8-en-32-aldehyde |
| 4,4-dimethyl-14a-formyl-5a-cholest-8-en-3b-ol |
| 4,4-dimethyl-14a-formyl-5a-cholesta-8-en-3b-ol |
| Q27159344 |
| DTXSID40974630 |
| (3s,5r,10s,13r,14s,17r)-3-hydroxy-4,4,10,13-tetramethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene-14-carbaldehyde |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 3beta-sterol | A sterol in which the hydroxy group at position 3 has beta- configuration. |
| tetracyclic triterpenoid | Any triterpenoid consisting of a tetracyclic skeleton. |
| 14alpha-formyl steroid | Any 14-formyl steroid in which the formyl group at position 14 has alpha- configuration. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Kandutsch-Russell Pathway (Cholesterol Biosynthesis) | 9 | 30 |
| cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | 9 | 37 |
| superpathway of cholesterol biosynthesis | 21 | 78 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.21) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||